NCT02762006 2024-03-18Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell CarcinomaCase Comprehensive Cancer CenterPhase 1 Completed29 enrolled
NCT02643303 2022-12-02A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersLudwig Institute for Cancer ResearchPhase 1/2 Completed58 enrolled 24 charts
NCT02118337 2021-06-01A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced MalignanciesMedImmune LLCPhase 1/2 Completed97 enrolled 40 charts